Table 3.
Novel designs to enhance TCR T-cell functional efficacy and safety, and overcome HLA-restriction limitations
Novel designs to enhance TCR T-cell functional efficacy and safety, and overcome HLA-restriction limitations
Novel designs to enhance TCR T-cell functional efficacy and safety, and overcome HLA-restriction limitations
Novel designs to enhance TCR T-cell functional efficacy and safety, and overcome HLA-restriction limitations

ATAM, artificial T-cell adaptor molecule; CML, chronic myeloid leukemia; CMV, cytomegalovirus; GVHD, graft-versus-host disease; LAG-3, lymphocyte activayion gene 3; NA, not applicable; NFAT, nuclear factor of activation T cells; PD1, programmed cell death 1; PDCD1, programmed cell death protein 1; PD-L1, programmed death ligand 1; TILs, tumor-infiltrating lymphocytes; TIM-3, T-cell immunoglobulin and mucin-domain containing 3; TNFα, tumor necrosis factor α; siRNA, small interfering RNA; STAR, synthetic TCR and antigen receptor; TACs, T-cell antigen couplers; tEGFR, truncated epidermal growth factor receptor; TRAC, T-cell receptor α constant; TRBC, T-cell receptor β constant; TRuCs, T-cell receptor fusion constructs. Figures created with BioRender.com: Gore S. (2025); https://BioRender.com/o91f055

References 93, 96, 99, 101, 102, 108, 123, and 131 are cited in this table.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal